GLOBAL – Expert Market Research’s recent report on the global contract development and manufacturing organization (CDMO) market found that it will be valued at US$268.51 billion in 2026 and US$588 billion by 2035, showing a compound annual growth rate (CAGR) of 9.10% for that period.
The report cites three factors that drive its market expansion, underscoring CDMOs’ importance in supporting the value chain of pharmaceutical and biotechnology companies:
- Increasing pharmaceutical outsourcing
- Rising demand for biologics and advanced therapies
- Preference for integrated end-to-end development services
Key Trends That Define Market Growth
As third-party partners, CDMOs have strengthened their clients’ operational efficiency and outcomes in two key areas:
-
- Integration of advanced drug delivery technologies: They utilize new tools to improve their capabilities in making drugs with complex formulations and to distribute them to the market faster.
- Brand consolidation and end-to-end service expansion: Multi-specialized CDMOs are partnering up to deliver efficient solutions to clients. This partnership also enables them to improve their operations, extend their global reach, and serve clients effectively.
Future-Proofing the Global CDMO Market
To protect this growth, CDMOs are implementing ways to evolve their operations in this “more constrained, complex outsourcing landscape.”
Here are the ways they’ll do so, according to an industry analysis shared at Contract Pharma:
- Remove disconnected processes and systems, automate back-and-forth tasks, and provide real-time transparency and data integrity to compete with clients’ internal teams
- Have the chief information officer (CIO) and the chief quality officer (CQO) align their priorities to deliver the required quality and infrastructure
- Double down on their geographical advantages in helping clients meet local regulatory compliance requirements
